Table 2 In vitro anti-antiarthritic activity of ECL using the bovine serum protein denaturation method
Group | Concentration (μg/mL) | % denaturation | % Inhibition of denaturation |
|---|---|---|---|
Control | – | 100 | 0 |
DICLO | 1000 | 9.85 ± 2.80 | 90.15 ± 2.81 |
750 | 25.63 ± 7.29 | 74.37 ± 7.29 | |
500 | 33.27 ± 0.01 | 66.73 ± 0.01 | |
200 | 42.04 ± 4.09 | 57.96 ± 4.09 | |
100 | 51.90 ± 2.79 | 48.10 ± 2.79 | |
50 | 61.58 ± 0.26 | 38.42 ± 0.26 | |
25 | 65.89 ± 0.01 | 34.11 ± 0.01 | |
ECL | 1000 | 27.00 ± 6.61 | 72.99 ± 6.61 |
750 | 42.20 ± 4.07 | 57.79 ± 2.75 | |
500 | 49.32 ± 2.75 | 50.67 ± 2.75 | |
200 | 54.60 ± 4.35 | 45.39 ± 4.35 | |
100 | 61.38 ± 3.11 | 38.61 ± 3.11 | |
50 | 65.82 ± 3.03 | 34.17 ± 3.03 | |
25 | 70.16 ± 0.10 | 29.84 ± 0.10 |